Stock Insights: Pfizer, McKesson, Parexel International March 27th

Pfizer Inc. (NYSE:PFE): Goldman said Pfizer could go further to unlock value following the Animal Health and Nutrition separation. The analyst believes the company could separate the Pharma and Generics businesses in two or three years, its the pipeline proves successful, and notes the CEO’s openness to unlock value further. Shares are Buy rated with a price target of $26, up from $25.

McKesson Corporation (NYSE:MCK): Baird raised its price target on McKesson to include its acquisition of the Katz Group. The firm also noted the company’s valuation and accretive nature of purchasing synergies from the deal. Shares are Outperform rated.

Parexel International Corp. (NASDAQ:PRXL): Baird raised its price target on PARAXEL citing ts backlog, accelerating revenue growth, improved margins, and strong balance sheet. Shares are Outperform rated.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at